<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671864</url>
  </required_header>
  <id_info>
    <org_study_id>P150601</org_study_id>
    <nct_id>NCT02671864</nct_id>
  </id_info>
  <brief_title>Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy</brief_title>
  <acronym>ANGIOSAFE 2</acronym>
  <official_title>Impact of Incretin-mimetic Hypoglycaemic Drugs on Diabetic Retinopathy in Type 2 Diabetic Patients and Study of Biomarkers in the Development of Severe Retinopathy: Angiosafe-T2D Study 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre National de la Recherche Scientifique, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Collège de France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Paris 5 - Rene Descartes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pierre and Marie Curie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Paris 7 - Denis Diderot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aix Marseille Université</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Experimental data suggest that GLP-1 promote endothelial cell growth and angiogenesis which
      may have beneficial effects on the cardiovascular system but harmful effects on the retina .
      This project investigate the possible link between incretin therapy and Severe Diabetic
      Retinopathy. The prevalence of severe DR in patients exposed to incretin therapy (GLP-1
      analogs or DPP4 inhibitors) is compared to that in non-exposed patients to these antidiabetic
      classes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is dedicated to investigate the impact of routinely prescribed hypoglycaemic
      treatments on the prevalence of severe retinopathy and to seek possible biomarkers of severe
      retinopathy. Hypoglycemic treatments taken by the patients are those prescribe by the usuel
      diabetogist in the context of routine care.

      The study includes T2D patients according to ADA criteria treated with any kind of
      hypoglycemic treatment and attending a diabetes center (One in Marseille, Department of
      Endocrinology, Hôpital Nord, Assistance Publique des Hôpitaux de Marseille, and one in Paris,
      Centre Universitaire du Diabète et de ses ComplicationsHôpital Lariboisière, Université Paris
      7, Assistance Publique des Hôpitaux de Paris).

      It consists of two visits: Visits1 &quot;Inclusion&quot; and Visits 2 &quot;three years after the
      inclusion&quot;. In each visit, the investigators will collect results of eye examination (fundus)
      and annual diabetes check up including anthropometric data, routine biology, diabetes
      complication status as well as medications taken by the patients (past and current). A
      bio-banking (blood, urine and hairs) will be also collected. Primary objective : to compare
      the prevalence of severe DR in patients exposed to incretin therapy (GLP-1 analogs or DPP4
      inhibitors) to that in non-exposed patients at baseline.

      Secondary objective: To compare the proportion of patients who worsen DR between V1
      (inclusion) and V2 (after 3-yr of treatment) in patients exposed to incretin-based therapy
      from baseline vs non-exposed patients: patients with no DR or mild to moderate non
      proliferative DR at V1 who progress to severe DR at V2.

      To evaluate whether the concentrations of angiogenic/inflammatory molecules and circulating
      endothelial and inflammatory cells are associated with severe DR in relation with the use of
      GLP-1 based therapy at V1 and V2.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2016</start_date>
  <completion_date type="Anticipated">April 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 11, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Severe DR at V1 (inclusion)</measure>
    <time_frame>at inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of severe DR at V2 (after 3 years of treatment)</measure>
    <time_frame>after 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of ANGPT4</measure>
    <time_frame>at inclusion and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of VEGF</measure>
    <time_frame>at inclusion and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of proinflammatory cytokines such as IL-1beta, IL-6, IL-8, TNF-alpha</measure>
    <time_frame>at inclusion and 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of blood circulating EPCs and PBMCs</measure>
    <time_frame>at inclusion and 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7200</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1: incretin-based therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with incretin-based therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: other antidiabetic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with other antidiabetic</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1: incretin-based therapy</intervention_name>
    <arm_group_label>1: incretin-based therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2: other antidiabetic</intervention_name>
    <arm_group_label>2: other antidiabetic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T2D patients according to ADA criteria treated with any kind of hypoglycaemic
             treatment

          -  Age above 18 years

        Exclusion Criteria:

          -  Type 1 diabetes

          -  Patients with cataract preventing DR grading

          -  Patients who had panretinal photocoagulation more than 6 years ago

          -  Documented pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GAUTIER Jean-François, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GAUTIER Jean-François, MD, PhD</last_name>
    <phone>33 1 49 95 90 20</phone>
    <email>jean-francois.gautier@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DUTOUR Anne, MD, PhD</last_name>
    <phone>33 4 91 38 29 63</phone>
    <email>anne.dutour@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne DUTOUR, MD, PhD</last_name>
      <phone>33 4 91 38 29 63</phone>
      <email>anne.dutour@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Bénédicte GABORIT, MD, PhD</last_name>
      <phone>33 491383650</phone>
      <email>benedicte.gaborit@ap-hm.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Département de Diabétologie - Hopital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>GAUTIER Jean-François, MD, PhD</last_name>
      <phone>33 1 49 95 90 20</phone>
      <email>jean-francois.gautier@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Incretin-based therapy</keyword>
  <keyword>GLP1</keyword>
  <keyword>Angiogenesis Inflammation</keyword>
  <keyword>Hypoglycaemic treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

